Abstract: Described is a B. breve strain for relieving rheumatoid arthritis and application thereof, belonging to the technical field of microorganisms. Described is a B. breve strain CCFM1078 possessing the effect of relieving rheumatoid arthritis, and shown to: promote secretion of anti-inflammatory factor IL-10 from RAW264.7 cells; reduce joint thickness, clinical score, and incidence of rats with rheumatoid arthritis; decrease levels of the pro-inflammatory cytokines TNF? and IL-1? in the serum of rats with rheumatoid arthritis; regulate the content of short-chain fatty acids in the feces of rats with rheumatoid arthritis; decrease the proportion of Th17 cells in the mesenteric lymph nodes of rats with rheumatoid arthritis; and reduce secretion of pro-inflammatory factor IL-6 from synovial cells.

Abstract: The disclosure discloses Bifidobacterium longum with the ability to relieve atopic dermatitis and its application, and belongs to the technical fields of microorganisms and medicine. The Bifidobacterium longum of the disclosure has the effects of relieving atopic dermatitis, and the effects are specifically embodied in: (1) significantly improving the degree of ear swelling in mice with atopic dermatitis; (2) significantly improving skin pathological symptoms and inflammatory cell infiltration in mice with atopic dermatitis; (3) significantly reducing the serum IgE level in mice with atopic dermatitis; (4) significantly reducing the levels of IL-4 and IL-13 in the skin tissues of mice with atopic dermatitis; and (5) significantly reducing the level of histamine in the skin tissues of mice with atopic dermatitis. Therefore, the Bifidobacterium longum has great application prospects in the preparation of products for the prevention and/or treatment of atopic dermatitis.

Abstract: The disclosure discloses a strain of Lactobacillus rhamnosus and application thereof in inhibiting Helicobacter pylori, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus rhamnosus CCFM1119. The Lactobacillus rhamnosus CCFM1119 can prevent and/or treat Helicobacter pylori infection, specifically embodied in that: (1) the Lactobacillus rhamnosus CCFM1119 can significantly relieve the gastrointestinal symptoms of patients with Helicobacter pylori infection; (2) the Lactobacillus rhamnosus CCFM1119 can significantly reduce the amount of colonization of Helicobacter pylori in patients with Helicobacter pylori infection; and (3) the Lactobacillus rhamnosus CCFM1119 can significantly increase the clearance rate of Helicobacter pylori in patients with Helicobacter pylori infection.

Abstract: The present disclosure discloses a strain of Lactobacillus pentosus capable of relieving pathological characteristics of mice infected with influenza virus and application thereof, and belongs to the field of microorganisms. The strain of L. pentosus CCFM1227 provided by the present disclosure can effectively improve the innate immune response of the mice infected with influenza virus so as to prevent and/or relieve influenza virus infection. In addition, the L. pentosus CCFM1227 of the present disclosure can be used for fermenting phloretin to produce deaminotyrosine. Therefore, the L. pentosus CCFM1227 has a great application prospect in preparation of products for preventing and/or relieving influenza virus infection.

Abstract: The disclosure discloses a strain of Bifidobacterium breve capable of preventing and relieving psoriasis and application thereof, belonging to the field of microbial technologies and medical technologies. The disclosure provides new uses of B. breve CCFM1078 in inhibiting the release of IL-23/Th17 axis related inflammatory factors, and relieving the psoriasis. The B. breve CCFM1078 of the disclosure can relieve the lesion skin of psoriasis-like mice, and can inhibit thickening of the skin epidermal layer, so that the IL-23 level, the IL-22 level and the IL-17 level in the skin decrease by 20.3%, 22.0% and 18.3%, respectively. The B. breve CCFM1078 has a great application prospect in the preparation of a product (such as a food, a drug or a health food) for preventing and/or treating psoriasis.

Abstract: The disclosure relates to Bifidobacterium longum for preventing and/or treating essential hypertension, and belongs to the technical fields of microorganisms and medicine. The B. longum CCFM752 provided by the disclosure prevents essential hypertension, specifically including: (1) significantly decreasing the O2- level, the H2O2 level and the NADPH oxidase activity in A7R5 cells stimulated with Angiotensin II; (2) significantly increasing the CAT activity in A7R5 cells, aortas of SHRs and serum of SHRs; (3) significantly decreasing the blood pressure level of SHRs; (4) significantly decreasing the aortic wall ROS level, the aortic wall NADPH oxidase activity, the aortic wall collagen level and the aortic wall thickness index of SHRs; and (5) significantly increasing the aortic wall eNOS activity of SHRs. It can be seen that the B. longum CCFM752 has great application prospects in preparation of products (such as food or drugs) for preventing and/or treating hypertension.

Abstract: The disclosure discloses Bacteroides fragilis for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides fragilis CCFM1020 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of hosts infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides fragilis CCFM1020 for relieving endotoxin infection has broad application prospects.

Abstract: The present disclosure discloses a strain of Lactobacillus fermentum capable of preventing and/or treating periodontitis and an application thereof, belonging to the field of microbiology technology. The present disclosure has screened to obtain a strain of L. fermentum CCFM1139. The L. fermentum CCFM1139 can alleviate periodontitis by inhibiting formation of mixed bacterial biofilms of Porphyromonas gingivalis, Prevotella intermedia and Fusobacterium nucleatum, thereby reducing the amount of biofilm by 52.45%, and can reduce the content of TNF-? from 131.37 pg/mL to 83.31 pg/mL and IL-8 from 147.70 pg/mL to 121.12 pg/mL in a periodontitis cell model, reduce colonization of the P. gingivalis and the F. nucleatum in the oral cavity by 1-2 orders of magnitude, and reduce the amount of the alveolar bone resorption from 1838.0 ?m to 805.7 ?m.

Abstract: The disclosure discloses Bacteroides ovatus for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides ovatus CCFM1021 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of mice infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides ovatus CCFM1021 for relieving endotoxin infection has broad application prospects.

Abstract: The disclosure discloses a strain of Lactobacillus rhamnosus and application thereof in inhibiting Helicobacter pylori, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus rhamnosus CCFM1119. The Lactobacillus rhamnosus CCFM1119 can prevent and/or treat Helicobacter pylori infection, specifically embodied in that: (1) the Lactobacillus rhamnosus CCFM1119 can significantly relieve the gastrointestinal symptoms of patients with Helicobacter pylori infection; (2) the Lactobacillus rhamnosus CCFM1119 can significantly reduce the amount of colonization of Helicobacter pylori in patients with Helicobacter pylori infection; and (3) the Lactobacillus rhamnosus CCFM1119 can significantly increase the clearance rate of Helicobacter pylori in patients with Helicobacter pylori infection.

Abstract: The disclosure discloses a B. breve strain capable of relieving rheumatoid arthritis and application thereof, and belongs to the technical field of microorganisms. The disclosure screens out a B. breve strain CCFM1078, and the B. breve CCFM1078 has the effect of relieving rheumatoid arthritis, being specifically embodied in: significantly promoting secretion of anti-inflammatory factor IL-10 from RAW264.7 cells; significantly reducing the joint thickness, clinical score and incidence of rats with rheumatoid arthritis; significantly decreasing the levels of pro-inflammatory cytokines TNF? and IL-1? in the serum of rats with rheumatoid arthritis; significantly regulating the content of short-chain fatty acids in the feces of rats with rheumatoid arthritis; significantly decreasing the proportion of Th17 cells in the mesenteric lymph nodes of rats with rheumatoid arthritis; and significantly reducing secretion of pro-inflammatory factor IL-6 from synovial cells.

Abstract: The disclosure discloses a probiotic mixed preparation with anti-influenza ability and application thereof, and belongs to the technical fields of microorganisms and medicines. The probiotic mixed preparation has anti-influenza effects, which are embodied in: (1) significantly reducing the degree of weight loss of influenza mice; (2) significantly improving the blood indexes of the influenza mice; (3) significantly improving the inflammation status of respiratory tract infections in the influenza mice; (4) significantly reducing the viral load in the lungs of the influenza mice (i.e., significantly inhibiting the replication and multiplication of influenza viruses in the influenza mice); and (5) significantly increasing the expression quantity of antiviral protein MxA in the lungs of the influenza mice. Therefore, the probiotic mixed preparation has great application prospects in preparation of a product for preventing and/or treating atopic dermatitis and even preventing and/or treating influenza.

Abstract: The present disclosure discloses multifunctional lactobacilli capable of relieving a toxic effect of perfluorooctanoic acid (PFOA) and use thereof, and belongs to the technical field of microorganisms.

Abstract: The disclosure discloses Bifidobacterium longum with the ability to relieve atopic dermatitis and its application, and belongs to the technical fields of microorganisms and medicine. The Bifidobacterium longum of the disclosure has the effects of relieving atopic dermatitis, and the effects are specifically embodied in: (1) significantly improving the degree of ear swelling in mice with atopic dermatitis; (2) significantly improving skin pathological symptoms and inflammatory cell infiltration in mice with atopic dermatitis; (3) significantly reducing the serum IgE level in mice with atopic dermatitis; (4) significantly reducing the levels of IL-4 and IL-13 in the skin tissues of mice with atopic dermatitis; and (5) significantly reducing the level of histamine in the skin tissues of mice with atopic dermatitis. Therefore, the Bifidobacterium longum has great application prospects in the preparation of products for the prevention and/or treatment of atopic dermatitis.

Abstract: The disclosure discloses Bacteroides ovatus for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides ovatus CCFM1021 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of mice infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides ovatus CCFM1021 for relieving endotoxin infection has broad application prospects.

Abstract: The disclosure discloses Bacteroides fragilis for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides fragilis CCFM1020 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of hosts infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides fragilis CCFM1020 for relieving endotoxin infection has broad application prospects.

Abstract: The disclosure discloses a probiotic mixed preparation with anti-influenza ability and application thereof, and belongs to the technical fields of microorganisms and medicines. The probiotic mixed preparation has anti-influenza effects, which are embodied in: (1) significantly reducing the degree of weight loss of influenza mice; (2) significantly improving the blood indexes of the influenza mice; (3) significantly improving the inflammation status of respiratory tract infections in the influenza mice; (4) significantly reducing the viral load in the lungs of the influenza mice (i.e., significantly inhibiting the replication and multiplication of influenza viruses in the influenza mice); and (5) significantly increasing the expression quantity of antiviral protein MxA in the lungs of the influenza mice. Therefore, the probiotic mixed preparation has great application prospects in preparation of a product for preventing and/or treating atopic dermatitis and even preventing and/or treating influenza.